Anglo Biopharma Limited
Company profile
DissolvedUnited Kingdom
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2022-04-30
IXBRL · 38 source facts · 14 selected values
Not assessedlegacy record
Accounts to 2022-04-30
IXBRL · 38 source facts · 14 selected values
Not assessed
legacy record
- Reporting period
- 2021-05-01 to 2022-04-30
- Extraction status
- Legacy / not assessed
- Numeric facts
- 20
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0003_10127664_20220430
- Source archive
- Accounts_Monthly_Data-February2023.zip
Accounts to 2021-04-30
IXBRL · 38 source facts · 14 selected values
Not assessedlegacy record
Accounts to 2021-04-30
IXBRL · 38 source facts · 14 selected values
Not assessed
legacy record
- Reporting period
- 2020-05-01 to 2021-04-30
- Extraction status
- Legacy / not assessed
- Numeric facts
- 20
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0101_10127664_20210430
- Source archive
- Accounts_Monthly_Data-January2022.zip
Accounts to 2020-04-30
IXBRL · 46 source facts · 14 selected values
Not assessedlegacy record
Accounts to 2020-04-30
IXBRL · 46 source facts · 14 selected values
Not assessed
legacy record
- Reporting period
- 2019-05-01 to 2020-04-30
- Extraction status
- Legacy / not assessed
- Numeric facts
- 28
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0082_10127664_20200430
- Source archive
- Accounts_Monthly_Data-September2020.zip
Accounts to 2019-04-30
IXBRL · 47 source facts · 13 selected values
Not assessedlegacy record
Accounts to 2019-04-30
IXBRL · 47 source facts · 13 selected values
Not assessed
legacy record
- Reporting period
- 2018-05-01 to 2019-04-30
- Extraction status
- Legacy / not assessed
- Numeric facts
- 29
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0073_10127664_20190430
- Source archive
- Accounts_Monthly_Data-December2019.zip
Accounts to 2018-04-30
IXBRL · 58 source facts · 12 selected values
Not assessedlegacy record
Accounts to 2018-04-30
IXBRL · 58 source facts · 12 selected values
Not assessed
legacy record
- Reporting period
- 2017-05-01 to 2018-04-30
- Extraction status
- Legacy / not assessed
- Numeric facts
- 14
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0056_10127664_20180430
- Source archive
- Accounts_Monthly_Data-July2018.zip
Accounts to 2017-04-30
IXBRL · 52 source facts · 5 selected values
Not assessedlegacy record
Accounts to 2017-04-30
IXBRL · 52 source facts · 5 selected values
Not assessed
legacy record
- Reporting period
- 2016-05-01 to 2017-04-30
- Extraction status
- Legacy / not assessed
- Numeric facts
- 6
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0050_10127664_20170430
- Source archive
- Accounts_Monthly_Data-January2018.zip
Registered details
10127664- Status
- Dissolved
- Type
- Unknown
- Incorporated
- —
- Jurisdiction
- —
- Registered office
- —
Classification
0 SIC codesNo SIC classification available.
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
4 matched grantsmAb manufacturing for future subunit vaccine platformLeadInnovate UK · Feasibility Studies · 2018-03-01 – 2019-02-28 · with 2 other participants£21,234awarded
mAb manufacturing for future subunit vaccine platformLead
Innovate UK · Feasibility Studies · 2018-03-01 – 2019-02-28 · with 2 other participants
£21,234
awarded
mAb manufacturing for future subunit vaccine platformLeadISCF · Feasibility Studies · 2018-03-01 – 2019-02-28 · with 2 other participants£78,011whole project
mAb manufacturing for future subunit vaccine platformLead
ISCF · Feasibility Studies · 2018-03-01 – 2019-02-28 · with 2 other participants
£78,011
whole project
mAb manufacturing for future subunit vaccine platformISCF · Feasibility Studies · 2018-03-01 – 2019-02-28 · with 2 other participants£78,011whole project
mAb manufacturing for future subunit vaccine platform
ISCF · Feasibility Studies · 2018-03-01 – 2019-02-28 · with 2 other participants
£78,011
whole project
Evaluation of the technical & commercial viability of developing an accelerated MERS vaccineLeadInnovate UK · Feasibility Studies · 2017-02-01 – 2018-01-31 · with 1 other participant£70,000awarded
Evaluation of the technical & commercial viability of developing an accelerated MERS vaccineLead
Innovate UK · Feasibility Studies · 2017-02-01 – 2018-01-31 · with 1 other participant
£70,000
awarded
Anglo Biopharma Limitedlead£70,000